$5,000 awarded to a postgraduate student to enhance their specialization in epidemiological and mental health problems in military personnel, Veterans and /or their families.

This award honours the legacy of Dr. Mark Zamorski, a specialist in epidemiological and health services research on mental health problems in military personnel and a steadfast CIMVHR supporter.  Dr. Zamorski led the Research and Analysis Section of the Directorate of Mental Health for the Canadian Forces Health Services Group from 2002 until his passing in 2018.

Eligibility Criteria:

• Be registered as a full-time student in either the final year of a master’s program or in the final 2 years of a PhD program at a Canadian university;
• Be conducting research that has significant potential to improve the mental health of Veteran or military populations, or their families;
• Exhibit significant potential for a high-impact research career in this area;
• Demonstrate a high level of quality in proposed research methodology, and excellent analytical and writing skills;
• Preference will be given to students studying at one of CIMVHR’s 44 partner universities.

The FY19 Defense Appropriation provides $3.2 million (M) to the Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP) to support innovative, high-impact Duchenne muscular dystrophy research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 DMDRP Program Announcement and General Application Instructions for the following award mechanism is posted on the Grants.gov.

IMPORTANT:  All applications for the FY19 DMDRP Idea Development Award must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology of DMD. Eligible therapeutic strategies include: gene therapy, genome editing, oligonucleotide therapies, exon skipping, protein therapeutics, and cell therapies.

Studies proposed under this award may include:

• Delivery to skeletal muscle and heart (ligand assisted, nanoparticles, identification of biological barriers to delivery, alternative vectors)
• Immunosuppression, and other strategies to deal with neutralizing antibodies
• Re-dosing
• Targeting muscle stem cells
• Cell based therapies, including but not limited to: selection of novel cell types, expansion, root of delivery, differentiation, and integration

Studies proposed under this award should not include:

• Therapies addressing secondary pathology of DMD (fibrosis, inflammation, muscle atrophy, oxidative stress, mitochondrial defects, abnormal peripheral circulation)
• Small molecules
• Efficacy testing absence of mechanistic understanding,
• Evaluation of standard vectors or delivery technologies

https://cdmrp.army.mil/funding/dmdrp

Idea Development Award

Principal Independent investigator (PI): Independent investigators at all academic levels (or equivalent) are eligible to be names as a PI.

• Supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accerale progress in improving outcomes for individuals with DMDM.
• Applications must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology or DMD.
• Preliminary data are required.
• Clinical trials are not allowed.
• Maximum funding of $350,000 in direct costs (plus indirect costs)
• Period of performance not to exceed 2 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the DMDRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk 
301-682-5507 
help@eBrap.org

The FY19 Defense Appropriation provides $20 million (M) to the Department of Defense Vision Research Program (VRP) to support impactful military-relevant vision research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 VRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

Applications submitted to the FY19 VRP must address at least one of the following Focus Areas:

• Eye injury or visual dysfunction as related to a military-relevant traumatic event.  Examples of military-relevant trauma may include, but are not limited to:

○        Blast, blunt, thermal, or chemical trauma

○        Trauma caused by directed energy weapons such as laser, microwaves, and particle beams

• Diagnosis and treatment of eye injuries in austere environments and prolonged field care settings

https://cdmrp.army.mil/funding/vrp

Focused Translational Team Science Award (FTTSA) – Preproposal due August 6, 2019

• The overall Principal Investigator (PI) must be an independent investigator at or above the level of Associate Professor (or equivalent) with demonstrated success in leading large collaborative research project(s).
• Leaders of individual projects may be independent investigators at all academic levels (or equivalent).
• The overall lead PI is required to devote a minimum of 20% effort to this award.

Preproposal is required; application submission is by invitation only.

• Supports a highly collaborative and translational team initiative that will fundamentally advance the understanding and treatment of eye injury and/or visual dysfunction that result from a military-relevant trauma.

• Must address one or more of the FY19 VRP Focus Areas.

• Applications shall include at least three but no more than five distinct research projects that together form a concerted and synergistic effort to address an overarching challenge.

• Preliminary data required for each individual project.

• One of the projects may include a pilot clinical trial where limited clinical testing of a novel intervention is conducted to inform the feasibility, rationale, and design of subsequent clinical trials.

• Must have a detailed Implementation Plan for participating research groups to coordinate efforts, facilitate collaboration, and create synergy.

○        Maximum funding of $5,000,000 for direct costs (plus indirect costs)

○        The maximum period of performance is 4 years.

Investigator-Initiated Research Award (IIRA) – Preproposal due August 6, 2019

Independent investigators at all academic levels (or equivalent).

Preproposal is required; application submission is by invitation only.

• Supports studies that will yield highly impactful discoveries or major advancements in research and/or patient care of eye injury and/or visual dysfunction as related to military-relevant trauma.
• Must address one or more of the FY19 VRP Focus Areas.
• Funding Level 1 supports exploratory, high-risk/high-reward research in the earliest stages of development. No preliminary data is required.
• Funding Level 2 supports the advancement of more mature research toward clinical translation.  Preliminary data required. 
• It is the responsibility of the applicant to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the stage and maturity of the research, rather than the amount of the budget.
• Clinical trials are not allowed

Funding Level 1:

• Maximum funding of $260,000 for direct costs (plus indirect costs)
• The maximum period of performance is 2 years.

Funding Level 2:

• Maximum funding of $500,000 for direct costs (plus indirect costs)
• The maximum period of performance is 3 years.

Translational Research Award (TRA) – Preproposal due August 6, 2019

Independent investigators at all academic levels (or equivalent).

Preproposal is required; application submission is by invitation only.

• Supports translational research that moves promising laboratory research into clinical applications.
• It is expected that an Investigational New Drug (IND)/Investigational Device Exemption (IDE) application will be submitted during or by the end of the period of performance.
• Must address one or more of the FY19 VRP Focus Areas.
• Preliminary data required.
  • May include a pilot clinical trial component where limited clinical limited clinical testing of a novel intervention is conducted to inform the feasibility, rationale, and design of subsequent clinical trials.
  • Maximum funding of $750,000 for direct costs (plus indirect costs)
  • The maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.  

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://ebrap.org/.  For more information about the VRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk 
301-682-5507 
help@eBrap.org

CIHR-ICR is committed to supporting and promoting the success of Early Career Researchers (ECRs). In response, this funding opportunity is part of a suite of activities ICR is undertaking in support of ECRs and intends to contribute to the long-term success of ECRs by giving them leadership opportunities and contributing to their development as future leaders. This funding opportunity will also focus on the mentorship of ECRs and building capacity with a specific emphasis on cancer research across the cancer control continuum. Recognizing ongoing efforts to harmonize across the tri-agencies, for the purpose of this funding opportunity, ECRs are referred to as New Investigators and defined in line with the TFRI definition, i.e., researchers who are within seven calendar years from the start of their first faculty-level appointment.

There has been a move towards more Collaborative Science with large teams. New Investigators may be challenged with getting involved and having a meaningful role in Team Science. The TFRI, a National Funding Agency, runs an annual competition to support New Investigators to be mentored as part of their funded teams’ activities. The current competition will expand this program to teams funded by TFRI and ICR. The goal of the program is to support outstanding New Investigators as they develop their careers as independent research scientists or clinician scientists, to undertake high-quality cancer research, while in close collaboration and mentorship with established TFRI or CIHR-ICR-funded research teams. Support will target high-quality research in all four funding pillars, providing information that may form the basis of innovative cancer prevention, diagnosis and/or treatment across the cancer control continuum.

The CIHR-ICRH/CAAIF/AstraZeneca/AllerGen Emerging Researcher Award is expected to:

• Increase Canadian research capacity in the area of asthma;
• Support the research careers of promising researchers;
• Produce high-quality research in asthma; and
• Contribute to knowledge translation activities.

This funding opportunity is expected to:

• Catalyze the transfer of health research knowledge related to sex, gender and diversity into health policy development and practice.
• Foster capacity development and the creation of best practices to support the sustainable application of evidence-based sex, gender and diversity analysis to health policies and programs.
• Support the scientifically rigorous evaluation of outcomes related to the integration of sex, gender and diversity in health policies and programs.

This clinician-scientist award program is a collaboration between the Canadian Lung Association (CLA), CIHR’s Institute of Circulatory and Respiratory Health (CIHR-ICRH) and AstraZeneca (AZ) Canada. The goal of the award is to support emerging clinician scientists (e.g., Doctor of Medicine, Doctor of Medicine–Doctor of Philosophy, Doctor of Dental Sciences, PhD–Respiratory Therapist, PhD–Registered Nurse, PhD-Physiotherapist, PhD–Occupational Therapist or equivalent) within the first five (5) years of their first faculty appointment in the establishment of their careers.

The Collaborative Health Research Projects (CHRP) Initiative supports innovative, interdisciplinary, collaborative research projects, requiring participation from the natural sciences or engineering community together with the health sciences community. The initiative requires the translation of the research results to knowledge/technology users (KTUs) and related stakeholders outside the academic or training environment. As such, the proposed research projects must have a strong focus on knowledge translation (KT) and lead to health and economic benefits for Canadians through more effective health services and products and/or a strengthened health care system. KTU organizations should be meaningfully engaged throughout the research process, as appropriate, to inform research planning and design. For more information on KT at CIHR, please see About KT. Applicants are also encouraged to refer to CIHR’s Guide to Knowledge Translation Planning at CIHR: Integrated and End-of-Grant Approaches. For additional guidance regarding knowledge/technology users, please consult CHRP - Frequently Asked Questions.

Projects must include training opportunities for trainees in collaborative and interdisciplinary research of relevance to health, preparing them for employment opportunities in the private, public or not for profit sectors. Given that interactions between personnel from academic institutions and other sectors contribute to knowledge sharing and the development of trainees, CIHR and NSERC encourage secondments, cross-appointments, co-supervision of students, internships, reciprocal laboratory visits and joint workshops.

A limited number of Travel Awards to PhD, MD, or MD/PhD students, and post-doctoral/medical/clinical fellows are available. The purpose of this program is to defray the travel costs associated with making a scientific presentation as a first author or presenter at a conference, symposium or other appropriate professional meeting.

A key goal of GlycoNet is to support research projects that are multi-disciplinary, as defined by the NCE program. Accordingly, this Request for Proposals seeks to fund projects that involve two or more research groups in different disciplines. Proposals that involve an investigator who is primarily funded on by one of the tri-council agencies (e.g., CIHR) working with others primarily funded by one or both of the other tri-council agencies (e.g., NSERC and/or SSHRC) will be viewed most favourably.